We serve Chemical Name:(5-methyl-1,3,4-thiadiazol-2-yl)hydrazine CAS:98025-62-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(5-methyl-1,3,4-thiadiazol-2-yl)hydrazine
CAS.NO:98025-62-8
Synonyms:5-methyl-1,3,4-thiadiazole-2-ylhydrazine;2-hydrazinyl-5-methyl-1,3,4-thiadiazole;2-Hydrazino-5-methyl-1,3,4-thiadiazole
Molecular Formula:C3H6N4S
Molecular Weight:130.17200
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:280ºC at 760 mmHg
Density:1.474g/cm3
Index of Refraction:1.701
PSA:92.07000
Exact Mass:130.03100
LogP:0.90540
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-methyl-1,3,4-thiadiazole-2-ylhydrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Hydrazino-5-methyl-1,3,4-thiadiazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Hydrazino-5-methyl-1,3,4-thiadiazole Use and application,5-methyl-1,3,4-thiadiazole-2-ylhydrazine technical grade,usp/ep/jp grade.
Related News: Regulators approved the shot in May but paused the deployment amid lingering concerns about blood clots. Japan has so far relied vaccines made by Pfizer Inc (PFE.N) and Moderna Inc (MRNA.O) in its inoculation push. methyl(3,3,3-trifluoropropyl)silane manufacturers After being on the ground since day one of this crisis, we immediately initiated our 3 phase recovery programs. $4000 GEM Bstrong Visa cards + $400 Walmart gift cards were given to all survivors and $1500 to families of the missing for short term incidentals. 2-Ethyl-5,6-dihydro-4H-thiazolo[4,5-e]indole-8-carboxylic Acid Ethyl Ester suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 2,2-dibenzyl-4-ethoxy-1-(5-phenyl-oxazol-2-yl)-butan-1-one vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. 2,2-dibenzyl-4-ethoxy-1-(5-phenyl-oxazol-2-yl)-butan-1-one vendor & factory.
